{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:17:25Z","timestamp":1790443045001,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jns.2021.120098","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:19:25Z","timestamp":1639653565000},"page":"120098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Current status of vaccines for substance use disorders: A brief review of human studies"],"prefix":"10.1016","volume":"434","author":[{"given":"Thanh Thuy","family":"Truong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.120098_bb0010","series-title":"Overdose Death Rates [Internet]","author":"Abuse NI on D","year":"2021"},{"issue":"S1","key":"10.1016\/j.jns.2021.120098_bb0015","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1089\/pop.2020.0230","article-title":"The opioid epidemic within the COVID-19 pandemic: drug testing in 2020","volume":"24","author":"Niles","year":"2021","journal-title":"Popul Health Manag."},{"key":"10.1016\/j.jns.2021.120098_bb0020","first-page":"995","article-title":"The rate hypothesis and agonist substitution approaches to cocaine abuse treatment","volume":"42","author":"Gorelick","year":"1998","journal-title":"Adv Pharmacol San Diego Calif."},{"issue":"1","key":"10.1016\/j.jns.2021.120098_bb0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s002130000624","article-title":"Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans","volume":"154","author":"Abreu","year":"2001","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.jns.2021.120098_bb0030","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1124\/dmd.31.11.1320","article-title":"Use of anti-(+)-methamphetamine monoclonal antibody to significantly Alter (+)-methamphetamine and (+)-amphetamine disposition in rats","volume":"31","author":"Laurenzana","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jns.2021.120098_bb0035","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1196\/annals.1441.027","article-title":"Substance abuse vaccines","volume":"1141","author":"Orson","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.jns.2021.120098_bb0040","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4161\/hv.5.4.7457","article-title":"Vaccines for cocaine abuse","volume":"5","author":"Orson","year":"2009","journal-title":"Hum Vaccin."},{"key":"10.1016\/j.jns.2021.120098_bb0045","series-title":"Clinical Immunology","first-page":"91","article-title":"6 - Antigens and antigen processing","author":"Rodgers","year":"2008"},{"issue":"1","key":"10.1016\/j.jns.2021.120098_bb0050","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0168-8278(05)80102-3","article-title":"Endocytosis of soluble IgG immune complex and its transport to lysosomes in hepatic sinusoidal endothelial cells","volume":"16","author":"Kosugi","year":"1992","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jns.2021.120098_bb0055","series-title":"Reference Module in Biomedical Sciences [Internet]","article-title":"Drug excretion","author":"Barreto","year":"2021"},{"issue":"36","key":"10.1016\/j.jns.2021.120098_bb0060","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1016\/j.vaccine.2019.06.074","article-title":"The continuing search for an addiction vaccine","volume":"37","author":"Ozgen","year":"2019","journal-title":"Vaccine."},{"issue":"11","key":"10.1016\/j.jns.2021.120098_bb0065","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14760584.2017.1378577","article-title":"Current status and future prospects for the development of substance abuse vaccines","volume":"16","author":"Heekin","year":"2017","journal-title":"Expert Rev Vaccines."},{"issue":"1","key":"10.1016\/j.jns.2021.120098_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nyas.14329","article-title":"Current status of immunotherapies for addiction","volume":"1489","author":"Xu","year":"2021","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2021.120098_bb0075","series-title":"The Health Consequences of Smoking -- 50 Years of Progress: A Report of the Surgeon General: (510072014-001) [Internet]","author":"United States Surgeon General","year":"2014"},{"issue":"8","key":"10.1016\/j.jns.2021.120098_bb0080","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpsyc.63.8.907","article-title":"Cigarette smoking saturates brain \u03b14 \u03b22 nicotinic acetylcholine receptors","volume":"63","author":"Brody","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jns.2021.120098_bb0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev-med-111314-033712","article-title":"The past, present, and future of nicotine addiction therapy","volume":"67","author":"Prochaska","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jns.2021.120098_bb0090","series-title":"Monitoring the Future 2020 Survey Results [Internet]","author":"Abuse NI on D","year":"2020"},{"issue":"3","key":"10.1016\/j.jns.2021.120098_bb0095","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2010.317","article-title":"Immunogenicity and smoking cessation outcomes for a novel nicotine immunotherapeutic","volume":"89","author":"Hatsukami","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.jns.2021.120098_bb0100","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/add.12573","article-title":"Efficacy of the nicotine vaccine 3\u2019-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial","volume":"109","author":"Hoogsteder","year":"2014","journal-title":"Addict Abingdon Engl."},{"key":"10.1016\/j.jns.2021.120098_bb0105","series-title":"Nabi Biopharmaceuticals Announces Results of First NicVAX(R) Phase III Clinical Trial [Internet]","author":"Biopharmaceuticals","year":"2011"},{"key":"10.1016\/j.jns.2021.120098_bb0110","series-title":"Nabi Biopharmaceuticals Announces Results of Second NicVAX(R) Phase III Clinical Trial [Internet]","year":"2011"},{"issue":"4","key":"10.1016\/j.jns.2021.120098_bb0115","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1176\/appi.ajp.2012.12060793","article-title":"Effect of a nicotine vaccine on nicotine binding to the beta2-nAChRs in vivo in human tobacco smokers","volume":"170","author":"Esterlis","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.jns.2021.120098_bb0120","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/add.12577","article-title":"Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task","volume":"109","author":"Havermans","year":"2014","journal-title":"Addict Abingdon Engl."},{"key":"10.1016\/j.jns.2021.120098_bb0125","author":"Celtic Pharma Development Services"},{"issue":"9","key":"10.1016\/j.jns.2021.120098_bb0130","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/ntr\/ntt003","article-title":"Niccine\u00ae, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial","volume":"15","author":"Tonstad","year":"2013","journal-title":"Nicotine Tob Res Off J Soc Res Nicotine Tob."},{"issue":"7","key":"10.1016\/j.jns.2021.120098_bb0135","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/eji.200526285","article-title":"A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity","volume":"35","author":"Maurer","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.jns.2021.120098_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002547","article-title":"A vaccine against nicotine for smoking cessation: a randomized controlled trial","volume":"3","author":"Cornuz","year":"2008","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jns.2021.120098_bb0145","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.intimp.2008.07.001","article-title":"Enhanced immunogenicity of a bivalent nicotine vaccine","volume":"8","author":"Keyler","year":"2008","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.jns.2021.120098_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076557","article-title":"Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice","volume":"8","author":"Pryde","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jns.2021.120098_bb0155","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nchem.2396","article-title":"Recent advances in the molecular design of synthetic vaccines","volume":"7","author":"Jones","year":"2015","journal-title":"Nat. Chem."},{"issue":"9","key":"10.1016\/j.jns.2021.120098_bb0160","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/npp.2015.64","article-title":"Effects of the nanoparticle-based vaccine, SEL-068, on nicotine discrimination in squirrel monkeys","volume":"40","author":"Desai","year":"2015","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.jns.2021.120098_bb0165","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.biomaterials.2016.08.028","article-title":"The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle based nicotine vaccine","volume":"106","author":"Hu","year":"2016","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.jns.2021.120098_bb0170","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.nano.2016.07.015","article-title":"A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy","volume":"13","author":"Zhao","year":"2017","journal-title":"Nanomedicine Nanotechnol Biol Med."},{"key":"10.1016\/j.jns.2021.120098_bb0175","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.biomaterials.2017.11.021","article-title":"Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction","volume":"155","author":"Zhao","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jns.2021.120098_bb0180","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health","first-page":"82","author":"Lipari","year":"2018"},{"issue":"6558","key":"10.1016\/j.jns.2021.120098_bb0185","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/378727a0","article-title":"Suppression of psychoactive effects of cocaine by active immunization","volume":"378","author":"Carrera","year":"1995","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jns.2021.120098_bb0190","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/archgenpsychiatry.2009.128","article-title":"Cocaine vaccine for the treatment of cocaine dependence in methadone maintained patients: a randomized double-blind placebo-controlled efficacy trial","volume":"66","author":"Martell","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jns.2021.120098_bb0195","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.04.003","article-title":"Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial","volume":"140","author":"Kosten","year":"2014","journal-title":"Drug Alcohol Depend."},{"issue":"11","key":"10.1016\/j.jns.2021.120098_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239780","article-title":"Cocaine vaccine dAd5GNE protects against moderate daily and high-dose \u201cbinge\u201d cocaine use","volume":"15","author":"Havlicek","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2021.120098_bb0205","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pbb.2016.09.008","article-title":"Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and Reacqusition using a choice procedure in Rhesus macaques","volume":"150\u2013151","author":"Evans","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"50","key":"10.1016\/j.jns.2021.120098_bb0210","doi-asserted-by":"crossref","first-page":"7989","DOI":"10.1016\/j.vaccine.2020.10.041","article-title":"Vaccination against cocaine using a modifiable dendrimer nanoparticle platform","volume":"38","author":"Lowell","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jns.2021.120098_bb0215","series-title":"Potency of methamphetamine U.S. by half-year 2012\u20132019 [Internet]","year":"2021"},{"issue":"1\u20132","key":"10.1016\/j.jns.2021.120098_bb0220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drugalcdep.2012.09.007","article-title":"A vaccine against methamphetamine attenuates its behavioral effects in mice","volume":"129","author":"Shen","year":"2013","journal-title":"Drug Alcohol Depend."},{"issue":"8","key":"10.1016\/j.jns.2021.120098_bb0225","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/ajad.12307","article-title":"Altered methamphetamine place conditioning in mice vaccinated with a succinyl-methamphetamine-tetanus-toxoid vaccine","volume":"24","author":"Haile","year":"2015","journal-title":"Am. J. Addict."},{"issue":"3","key":"10.1016\/j.jns.2021.120098_bb0230","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00213-019-05399-6","article-title":"Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors","volume":"237","author":"Keller","year":"2020","journal-title":"Psychopharmacology"},{"issue":"35","key":"10.1016\/j.jns.2021.120098_bb0235","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.intimp.2016.03.028","article-title":"Optimization of a methamphetamine conjugate vaccine for antibody production in mice","author":"Stevens","year":"2016","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.jns.2021.120098_bb0240","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1021\/acs.jmedchem.6b00084","article-title":"Methamphetamine vaccines: improvement through Hapten design","volume":"59","author":"Collins","year":"2016","journal-title":"J. Med. Chem."},{"issue":"31","key":"10.1016\/j.jns.2021.120098_bb0245","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1039\/C4CC00682H","article-title":"Lipid tucaresol as an adjuvant for methamphetamine vaccine development","volume":"50","author":"Collins","year":"2014","journal-title":"Chem Commun Camb Engl."},{"issue":"36","key":"10.1016\/j.jns.2021.120098_bb0250","doi-asserted-by":"crossref","first-page":"14089","DOI":"10.1021\/jacs.9b07294","article-title":"Consequence of Hapten stereochemistry: an efficacious methamphetamine vaccine","volume":"141","author":"Olson","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.jns.2021.120098_bb0255","doi-asserted-by":"crossref","first-page":"12060","DOI":"10.1038\/srep12060","article-title":"A nanotechnology-based platform for extending the pharmacokinetic and binding properties of anti-methamphetamine antibody fragments","volume":"5","author":"Nanaware-Kharade","year":"2015","journal-title":"Sci. Rep."},{"issue":"34","key":"10.1016\/j.jns.2021.120098_bb0260","doi-asserted-by":"crossref","first-page":"897","DOI":"10.15585\/mmwr.mm6634a2","article-title":"trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region \u2014 United States, 2006\u20132015","volume":"66","author":"O\u2019Donnell","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.jns.2021.120098_bb0265","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths \u2014 United States, 2013\u20132019","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jns.2021.120098_bb0275","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pnpbp.2013.05.012","article-title":"A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats","volume":"45","author":"Kosten","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"22","key":"10.1016\/j.jns.2021.120098_bb0280","doi-asserted-by":"crossref","first-page":"9036","DOI":"10.1073\/pnas.1219159110","article-title":"Dynamic vaccine blocks relapse to compulsive intake of heroin","volume":"110","author":"Schlosburg","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.jns.2021.120098_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184876","article-title":"Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse","volume":"12","author":"Raleigh","year":"2017","journal-title":"PLoS One"},{"issue":"171","key":"10.1016\/j.jns.2021.120098_bb0290","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","article-title":"A review: fentanyl and non-pharmaceutical fentanyls","author":"Suzuki","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"11","key":"10.1016\/j.jns.2021.120098_bb0295","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/anie.201511654","article-title":"Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs","volume":"55","author":"Bremer","year":"2016","journal-title":"Angew Chem Int Ed Engl."},{"key":"10.1016\/j.jns.2021.120098_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107730","article-title":"Vaccine blunts fentanyl potency in male rhesus monkeys","volume":"158","author":"Tenney","year":"2019","journal-title":"Neuropharmacology."},{"issue":"1","key":"10.1016\/j.jns.2021.120098_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00329-0","article-title":"Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge","volume":"6","author":"Stone","year":"2021","journal-title":"Npj Vaccines."},{"key":"10.1016\/j.jns.2021.120098_bb0310","author":"Comer"},{"issue":"9","key":"10.1016\/j.jns.2021.120098_bb0315","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s00213-020-05558-0","article-title":"Active vaccination reduces reinforcing effects of MDPV in male Sprague-Dawley rats trained to self-administer cocaine","volume":"237","author":"McClenahan","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jns.2021.120098_bb0320","series-title":"Synthetic Cathinones (\u201cBath Salts\u201d) DrugFacts [Internet]","author":"Abuse NI on D","year":"2020"},{"key":"10.1016\/j.jns.2021.120098_bb0325","series-title":"Synthetic Drugs (a.k.a. K2, Spice, Bath Salts, etc.) [Internet]","year":"2021"},{"issue":"3","key":"10.1016\/j.jns.2021.120098_bb0330","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2607","article-title":"Profile, effects, and toxicity of novel psychoactive substances: a systematic review of quantitative studies","volume":"32","author":"Assi","year":"2017","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.jns.2021.120098_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2016.12.005","article-title":"Active vaccination attenuates the psychostimulant effects of \u03b1-PVP and MDPV in rats","volume":"116","author":"Nguyen","year":"2017","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.jns.2021.120098_bb0340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1021\/jacsau.0c00057","article-title":"Broadly neutralizing synthetic cannabinoid vaccines","volume":"1","author":"Lin","year":"2021","journal-title":"JACS Au."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21028008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21028008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:58:07Z","timestamp":1758383887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21028008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":66,"alternative-id":["S0022510X21028008"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.120098","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of vaccines for substance use disorders: A brief review of human studies","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.120098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120098"}}